GLPwatch
Post Marketing Surveillance Study of Byetta ™ (Exenatide) Use Among Filipino Patients
NCT00622323 · Completed
Last updated 2026-05-28This study tracks side effects experienced by Filipino adults with type 2 diabetes who are treated with the medication exenatide.
Status Completed The study has finished.
Type Observational
Participants 41 people
Who can join Ages 18+ · all sexes
Timeline Started 2008-02 · est. completion 2009-09
Where 3 sites · Philippines
What this study is testing ClinicalTrials.gov NCT00622323 ↗
Description as written by the study sponsor.
This is a prospective, non-interventional, post marketing surveillance study to determine the proportion of patients experiencing an adverse event and a list of the experienced adverse events, serious and non-serious, that would occur among Filipino patients with type 2 diabetes mellitus who are treated with exenatide who are taking metformin, a sulfonylurea or a combination of metformin and a sulfonylurea but have not achieved adequate glycemic control.
| Main thing measured | To determine the proportion of patients experiencing an adverse event and a list of the experienced adverse events, that would occur among Filipino patients with type 2 diabetes and inadequate glycemic control treated with exenatide |
|---|---|
| Sponsor | AstraZeneca |
| Conditions studied | Type 2 Diabetes Mellitus |
| GLP-1 drugs | exenatide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00622323 ↗